Literature DB >> 19423112

Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites.

Zeenat Ali1, Allison A Ellington, Thomas H Mosley, Iftikhar J Kullo.   

Abstract

Osteoprotegerin (OPG), a member of tumor necrosis factor receptor superfamily, has been implicated in vascular disease. We investigated the association of serum OPG with the ankle-brachial index (ABI) and urine albumin:creatinine ratio (UACR), in a bi-ethnic cohort of 1324 African-Americans (mean age 64 years, 71% women) and 1237 non-Hispanic whites (mean age 59 years, 57% women) belonging to hypertensive sibships. Serum levels of OPG were measured by solid phase sandwich immunoassay. ABI was measured using a standard protocol and peripheral arterial disease (PAD) defined as ABI<0.90. UACR was expressed as mg albumin/gm creatinine. Multivariable regression analysis using generalized estimating equations (GEE) were performed to assess whether serum OPG levels were associated with ABI and UACR. After adjustment for conventional risk factors (age, sex, diabetes, waist circumference, history of smoking, total and HDL cholesterol, hypertension), prior history of myocardial infarction or stroke, and medication (renin-angiotensin-aldosterone system inhibitors, statins, aspirin, estrogen) use, higher OPG levels were significantly associated with lower ABI and higher UACR in African-Americans (P=0.001 and P<0.0001, respectively) and non-Hispanic whites (P=0.017 and P=0.002, respectively); the association remained significant after further adjustment for plasma C-reactive protein (CRP) in both ethnic groups. In multivariable logistic regression analysis, higher OPG levels were associated with PAD in African-Americans, independent of the covariates listed above (P=0.026); the association remained significant after additional adjustment for plasma CRP (P=0.047). In non-Hispanic whites, the association of higher OPG levels with PAD was of borderline significance after adjustment for the relevant covariates (P=0.106). We conclude that higher OPG levels are associated with lower ABI and higher UACR, independent of conventional risk factors and plasma CRP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423112      PMCID: PMC3773523          DOI: 10.1016/j.atherosclerosis.2009.03.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  42 in total

Review 1.  Roles of endothelial dysfunction in coronary artery disease.

Authors:  M A Forgione; J A Leopold; J Loscalzo
Journal:  Curr Opin Cardiol       Date:  2000-11       Impact factor: 2.161

2.  Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP).

Authors: 
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

Review 3.  Medical treatment of peripheral arterial disease and claudication.

Authors:  W R Hiatt
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

4.  Nitric oxide is a physiological substrate for mammalian peroxidases.

Authors:  H M Abu-Soud; S L Hazen
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

Review 5.  Current medical therapies for patients with peripheral arterial disease: a critical review.

Authors:  Judith G Regensteiner; William R Hiatt
Journal:  Am J Med       Date:  2002-01       Impact factor: 4.965

6.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.

Authors:  S Sugiyama; Y Okada; G K Sukhova; R Virmani; J W Heinecke; P Libby
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

7.  Association between myeloperoxidase levels and risk of coronary artery disease.

Authors:  R Zhang; M L Brennan; X Fu; R J Aviles; G L Pearce; M S Penn; E J Topol; D L Sprecher; S L Hazen
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

8.  Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo.

Authors:  S L Hazen; R Zhang; Z Shen; W Wu; E A Podrez; J C MacPherson; D Schmitt; S N Mitra; C Mukhopadhyay; Y Chen; P A Cohen; H F Hoff; H M Abu-Soud
Journal:  Circ Res       Date:  1999-11-12       Impact factor: 17.367

9.  A biomarker panel for peripheral arterial disease.

Authors:  Eric T Fung; Andrew M Wilson; Fujun Zhang; Nathan Harris; Kim A Edwards; Jeffrey W Olin; John P Cooke
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

10.  Myeloperoxidase, a leukocyte-derived vascular NO oxidase.

Authors:  Jason P Eiserich; Stephan Baldus; Marie-Luise Brennan; Wenxin Ma; Chunxiang Zhang; Albert Tousson; Laura Castro; Aldons J Lusis; William M Nauseef; C Roger White; Bruce A Freeman
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  9 in total

1.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

2.  Type 2 diabetes does not attenuate racial differences in coronary calcification.

Authors:  Alisha N Wade; Sean Fedyna; Nehal N Mehta; Caitlin St Clair; Naeema Ginwala; Rama K Krishna; Atif N Qasim; Seth Braunstein; Nayyar Iqbal; Mark H Schutta; Muredach P Reilly
Journal:  Diabetes Res Clin Pract       Date:  2010-11-09       Impact factor: 5.602

3.  Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease.

Authors:  A Gaudio; F Muratore; V Fiore; R Rapisarda; S S Signorelli; C E Fiore
Journal:  Osteoporos Int       Date:  2015-02-12       Impact factor: 4.507

4.  Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease.

Authors:  Zi Ye; Zeenat Ali; George G Klee; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2013-01-11       Impact factor: 2.689

Review 5.  Novel markers of peripheral arterial disease.

Authors:  Farhan J Khawaja; Iftikhar J Kullo
Journal:  Vasc Med       Date:  2009-11       Impact factor: 3.239

6.  High circulating osteoprotegerin levels are associated with non-zero blood groups.

Authors:  Elod Erno Nagy; Timea Varga-Fekete; Attila Puskas; Piroska Kelemen; Zoltan Brassai; Katalin Szekeres-Csiki; Timea Gombos; Maria Csilla Csanyi; Jolan Harsfalvi
Journal:  BMC Cardiovasc Disord       Date:  2016-05-26       Impact factor: 2.298

Review 7.  Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease.

Authors:  Pavel Poredoš; Mišo Šabovič; Mojca Božič Mijovski; Jovana Nikolajević; Pier Luigi Antignani; Kosmas I Paraskevas; Dimitri P Mikhailidis; Aleš Blinc
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

8.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

9.  Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.

Authors:  Yixin Niu; Weiwei Zhang; Zhen Yang; Xiaoyong Li; Jie Wen; Suijun Wang; Hongmei Zhang; Xuanchun Wang; Houguang Zhou; Wenjun Fang; Li Qin; Qing Su
Journal:  BMC Cardiovasc Disord       Date:  2015-08-11       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.